RegenETP Inc. (RGTPQ)
Market Cap | 66.39K |
Revenue (ttm) | 73,000 |
Net Income (ttm) | -8.31M |
Shares Out | 7.32M |
EPS (ttm) | -1.67 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 2,433 |
Open | 0.0087 |
Previous Close | 0.0095 |
Day's Range | 0.0087 - 0.0246 |
52-Week Range | n/a |
Beta | 0.82 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | n/a |
About RGTPQ
RegenETP, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, o... [Read more]
Financial Performance
In 2022, RegenETP's revenue was $814,000, a decrease of -91.34% compared to the previous year's $9.40 million. Losses were -$7.83 million, -74.05% less than in 2021.
Financial StatementsNews

PolarityTE Announces Entry Into a Letter of Intent For Acquisition of the Company
SALT LAKE CITY , Dec. 27, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials (the "Company"), today announced that i...

PolarityTE Reports Third Quarter 2022 Financial Results and Provides Business Update
SALT LAKE CITY , Nov. 10, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and rep...

PolarityTE Confirms Receipt of Unsolicited, Non-Binding Offer to Acquire the Company
SALT LAKE CITY , Nov. 9, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today confirmed that on November 1, 2022...

PolarityTE to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022
SALT LAKE CITY , Sept. 13, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced it will present at the...

PolarityTE Announces Resignation of Jeff Dyer from its Board of Directors
SALT LAKE CITY , Sept. 8, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that Jeff Dyer, PhD, has...

PolarityTE Reports Second Quarter 2022 Financial Results and Provides Business Update
PolarityTE to host conference call and webcast today, August 11, 2022, at 4:30 p.m. ET SALT LAKE CITY , Aug. 11, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing ...

PolarityTE to Report Q2 2022 Financial Results on August 11, 2022
SALT LAKE CITY , Aug. 1, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ: PTE) today announced that it will report results for the quarter ended June 30, 2022, by press release on Thursday, August 11, 2...

PolarityTE Announces $8.0 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules
SALT LAKE CITY , June 6, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that it has entered into...

PolarityTE to Attend H.C. Wainwright Global Investment Conference
SALT LAKE CITY , May 23, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced that Richard Hague, Chief Executive Officer, and Nikolai Sopko, MD, PhD, Chief Scientific Officer, will pre...

PolarityTE to Effectuate 1-for-25 Reverse Stock Split
SALT LAKE CITY , May 16, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that the Company will eff...

PolarityTE Reports First Quarter 2022 Financial Results and Provides Business Update
PolarityTE to host conference call and webcast today, May 16, 2022, at 8:30 a.m. ET SALT LAKE CITY , May 16, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing rege...

PolarityTE Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to SkinTE®
SALT LAKE CITY , May 13, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced that the U.S. Food and Drug Administration (FDA) granted a Regenerative Medicine Advanced Therapy (RMAT) de...

PolarityTE to Report Q1 2021 Financial Results on May 16, 2022
SALT LAKE CITY , May 6, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the three-month period ended March 31, 2022, by press release on Monday, May...

PolarityTE Announces First Subject Enrolled in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers
SALT LAKE CITY , May 3, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced the enrollment of the first subject in the Phase III pivotal study evaluating SkinTE in the investigational ...

Why Is PolarityTE Stock Up 85% Today?
PolarityTE Inc (NASDAQ: PTE) shares are surging Tuesday as traders circle bullish commentary from a popular trader in the "FinTwit" community. "FinTwit" is an abbreviated term for "Financial Twitter,"...

PolarityTE Reports Fiscal Year 2021 Financial Results and Provides Business Update
PolarityTE to host conference call and webcast today, March 30, 2022, at 8:30 a.m. ET SALT LAKE CITY , March 30, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing ...

PolarityTE Announces Closing of $5.0 Million Registered Direct Offering
SALT LAKE CITY, March 16, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) ("PolarityTE" or the "Company"), a biotechnology company developing regenerative tissue products and biomaterials, today a...

PolarityTE Announces $5.0 Million Registered Direct Offering
SALT LAKE CITY, March 16, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) ("PolarityTE" or the "Company"), a biotechnology company developing regenerative tissue products and biomaterials, today a...

PolarityTE to Report Fiscal Year 2021 Financial Results on March 30, 2022
SALT LAKE CITY, March 10, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the year ended December 31, 2021, by press release on Wednesday, March 30,...

PolarityTE's SkinTE Meets Primary, Secondary Goals In Venous Leg Ulcers Trial
PolarityTE Inc (NASDAQ: PTE) has announced results from a multi-center randomized controlled trial evaluating SkinTE for Venous Leg Ulcers (VLU). There were twenty-nine participants, with 14 receiving...

PolarityTE Announces Allowance of Fourth U.S. Patent
SALT LAKE CITY, Feb. 17, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced the U.S. Patent and Trad...

FDA Approves PolarityTE's Phase 3 Study Of SkinTE In Chronic Cutaneous Ulcer
The FDA has signed off PolarityTE Inc's (NASDAQ: PTE) investigational new drug (IND) application to evaluate SkinTE to treat chronic cutaneous ulcers. This follows the Company satisfactorily addressi...

PolarityTE Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to Support Chronic Cutaneous Ulcer Indication
SALT LAKE CITY, Jan. 18, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced that the U.S. Food and D...

PolarityTE Announces Submission of Complete Response to FDA's Clinical Hold Correspondence for SkinTE® Investigational New Drug Application
SALT LAKE CITY, Dec. 20, 2021 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that it has submitted its...

POLARITYTE ALERT: Bragar Eagel & Squire, P.C. is Investigating PolarityTE, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)-- #PTE--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against PolarityTE, Inc. (NASDAQ: PTE) on behalf o...